Portal de investigación
Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Pose, A
- Manzano, L
- Gavira, JJ
- López Granados A
- Aramburu, O
- Arevalo, JC
- Mendez, M
- Comin, J
- Manito, N
Grupos
Abstract
Heart failure (HF) is currently one of the most significant healthcare problems in Spain and has a continuously increasing prevalence. Advances in our understanding of the various biological responses that promote cardiac remodelling and pulmonary venous congestion constitute the basis of current treatment. This article, prepared by members of the HF groups of the Spanish Society of Cardiology and the Spanish Society of Internal Medicine, discusses the current therapeutic strategies for patients with congestion refractory to diuretic treatment. The article includes our clinical experience with the use of tolvaptan as an additional treatment for congestion associated with hyponatraemia. To this end, we propose an algorithm for the use of tolvaptan in patients with congestive HF, natraemia < 130 mEq/l and poor response to conventional diuretic treatment. (C) 2017 Elsevier Espana, S.L.U. and Sociedad Espanola de Medicina Interna (SEMI). All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0014-2565, 1578-1860
- Tipo:
- Article
- Páginas:
- 398-404
- PubMed:
- 28372784
- Factor de Impacto:
- 0,218 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
REVISTA CLINICA ESPANOLA EDICIONES DOYMA S A
Citas Recibidas en Web of Science: 3
Documentos
- No hay documentos
Filiaciones
Keywords
- Heart failure; Congestion; Refractory; Diuretic; Tolvaptan; Recommendations
Campos de Estudio
Cita
Pose A,ALMENAR L,Manzano L,Gavira JJ,López A,DELGADO J,Aramburu O,Arevalo JC,Mendez M,Comin J,Manito N. Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan. Rev. Clin. Esp. 2017. 217. (7):p. 398-404. IF:1,184. (3).